From the Lancet Respiratory Medicine, Vol 9, Issue 7, July 1, 2021
The administration of inhaled Budesonide for a short duration in adults might be effective in the treatment of early COVID-19.
A reduction of 91% of clinical deterioration has been demonstrated and is equivalent to the effectiveness seen after the use of COVID-19 vaccines.
Inhaled budesonide is an easy, harmless, well studied, modestly priced medication and is widely available.
Access Article Here
